Skip to main content


Fig. 4 | Molecular Neurodegeneration

Fig. 4

From: Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

Fig. 4

Armanezumab bound to pathological tau in brain tissues from inferior parietal gyrus of AD (a), midfrontal cortices of both Pick’s Disease (b) and Frontotemporal Dementia (c), while no binding was observed in the inferior parietal gyrus of non-AD brain (d). Adjacent brain sections stained with other antibodies against pathological tau such as PHF1 (e-g), AT8 (i-k), AT100 (m-o), N-terminal tau TNT1 (q-s), as well as HT7 anti-total tau (u-w), showed similar patterns of pathological profiles in perikarya and neuritic processes, while no binding was observed in the adjacent sections from the control brain (d, h, l, p, t, x). Original magnification 60X, scale bar =20 um

Back to article page